Abstract
AbstractThe neurotracer 6-[18F]FDOPA has been, for many years, a powerful tool in PET imaging of neuropsychiatric diseases, movement disorders and brain malignancies. More recently, it also demonstrated good results in the diagnosis of other malignancies such as neuroendocrine tumours, pheochromocytoma or pancreatic adenocarcinoma.The multiple clinical applications of this tracer fostered a very strong interest in the development of new and improved methods for its radiosynthesis. The no-carrier-added nucleophilic 18F-fluorination process has gained increasing attention, in recent years, due to the high molar activities obtained, when compared with the other methods although the radiochemical yield remains low (17–30%). This led to the development of several nucleophilic synthetic processes in order to obtain the product with molar activity, radiochemical yield and enantiomeric purity suitable for human PET studies.Automation of the synthetic processes is crucial for routine clinical use and compliance with GMP requirements. Nevertheless, the complexity of the synthesis makes the production challenging, increasing the chance of failure in routine production. Thus, for large-scale clinical application and wider use of this radiopharmaceutical, progress in the automation of this complex radiosynthesis is of critical importance.This review summarizes the most recent developments of 6-[18F]FDOPA radiosynthesis and discusses the key issues regarding its automation for routine clinical use.
Funder
COMPETE
Fundação para a Ciência e a Tecnologia
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmacology,Radiology, Nuclear Medicine and imaging,Analytical Chemistry
Reference72 articles.
1. Adam MJ, Jivan S. Synthesis and purification of l-6-[18F]fluorodopa. Int J Radiat Appl Instrumentation Part A Appl Radiat Isot. 1988;39(12):1203–6.
2. Adam MJ, Ruth TJ, Grierson JR, Abeysekera B, Pate BD. Routine Synthesis of L- [18F] 6-Fluorodopa with Fluorine- 18 Acetyl Hypofluorite. J Nucl Med. 1986;27:1462–6.
3. Balogova S, Talbot JN, Nataf V, Michaud L, Huchet V, Kerrou K, et al. 18F-Fluorodihydroxyphenylalanine vs other radiopharmaceuticals for imaging neuroendocrine tumours according to their type. Eur J Nucl Med Mol Imaging. 2013;40(6):943–66.
4. Bishop A, Satyamurthy N, Bida G, Barrio JR. Chemical reactivity of the 18F electrophilic reagents from the 18O(p,n)18F gas target systems. Nucl Med Biol. 1996;23(5):559–65.
5. Bose SK, Turkheimer FE, Howes OD, Mehta MA, Cunliffe R, Stokes PR, et al. Classification of schizophrenic patients and healthy controls using [18F] fluorodopa PET imaging. Schizophr Res. 2008;106(2–3):148–55.
Cited by
6 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献